Title: Phase 3 randomised study of canfosfamide (Telcyta((R)), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
Authors: Vergote, Ignace ×
Finkler, N
Del Campo, J
Lohr, A
Hunter, J
Matei, D
Kavanagh, J
Vermorken, J B
Meng, L
Jones, M
Brown, G
Kaye, S #
Issue Date: Sep-2009
Publisher: Pergamon
Series Title: European Journal of Cancer vol:45 issue:13 pages:2324-2332
Abstract: RATIONALE: Canfosfamide HCl (CAN) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis. CAN is synergistic in vitro with carboplatin, paclitaxel and anthracyclines. METHODS: Patients with platinum-refractory or -resistant ovarian cancer (OC) who had progressed on second-line therapy with pegylated liposomal doxorubicin (PLD) or topotecan (TOPO), were randomised between CAN 1000mg/m(2) IV q 3weeks or to either PLD 50mg/m(2) IV q 4weeks or TOPO 1.5mg/m(2) IV d1-5 q 3weeks. RESULTS: About 461 patients were randomised after stratification for ECOG performance status, prior therapy, and bulky (>5cm) disease. Groups were well balanced. In the control arm 58% and 42% were treated with PLD and TOPO, respectively. CAN was well tolerated with the most common grade 3-4 toxicities of 5% anaemia, 4% neutropaenia (no febrile neutropaenia), 4% thrombocytopaenia, and 7% vomiting. Progression-free survival (PFS) and overall survival (OS) were significantly higher in the control arm (p<0.001 and p<0.01, respectively). In a subgroup analysis PFS and OS tended to be higher with PLD than with TOPO. CONCLUSION: CAN was well tolerated. This is the first randomised study showing an increased OS with third-line therapy. This might have important consequences for other recurrent OC trials.
ISSN: 0959-8049
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science